Global Retinal Biologics Market Overview:
Biologics are effective medicines made up of small components such as sugars, proteins, or DNA, or entire cells or tissues. Retinal biologics are bioengineered particles implanted in the eyes to treat chronic retinal diseases. The majority of biologics are derived from living organisms, such as plant or animal cells or microorganisms. Macugen, Humira, Lucentis, Eylea, and other retinal biologics are used to treat retinal diseases. With the increase in diabetes across the world; the demand for retinal biologics is also increasing. Some of the players profiled in the study are Spark Therapeutics (United States), Regeneron Pharmaceuticals, Inc. (United States), AbbVie Inc. (United States), Johnson & Johnson (United States), Amgen Inc. (United States), Novartis International AG (Switzerland), ALLERGAN (Ireland), Janssen Biotech (United States), Ocular Therapeutix (United States), Samsung Biologics (South Korea) and Spark Therapeutics (United States).
On the basis of geography, the market of Retinal Biologics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Diagnostic Tests, the sub-segment i.e. Amsler grid test will boost the Retinal Biologics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Disease Indication, the sub-segment i.e. Retinal Tear will boost the Retinal Biologics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Market Growth Drivers
- Need of Retinal Biologics to Treat Retinal Diseases
- Growing Diabetic Population
- Advancements in Technology of Retinal Biologics
- High Cost Associated with Retinal Biologics
- Increasing Awareness About the Retinal Disease Will Boost the Demand of Retinal Biologics
- Growing Investment in Medical Infrastructure by Developing Countries Will Increase the Demand of Retinal Biologics
- Need of High R&D Expenses for The Development of Retinal Biologics
- Lack of Enough Skilled Employees to Operate in Manufacture of Retinal Biologics
Key Market Developments:
On 24th Feb 2014, The US Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals, Inc.'s supplementary Biologics LicenInjection for the treatment of Macular Edema after Branch Retinal Vein Occlusion for standard review (BRVO). The goal for a regular review of a sBLA under the Prescription Drug User Fee Act (PDUFA) is ten months from application.
Target Audience:Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Retinal Biologics Manufacturers, Suppliers, and Distributors, Raw Material Suppliers, Government Regulatory and Research Organizations, End-Use Industries and Others
Major Objectives Focused through this Study To define, describe, and forecast the Global Retinal Biologics market on the basis of product  , application [Hospitals, Clinics, Research Organizations and Others], key regions and end user
To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
To provide market size for various segments of the Retinal Biologics market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
To strategically profile the key players and analyzing their market shares and core competencies in the Retinal Biologics industry
To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market
Available Customization: Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are .
** Confirmation on availability of data would be informed prior purchase
While framing the research framework, major and emerging players operating in the Retinal Biologics market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.